Immune checkpoint inhibitors (ICIs) directing the programmed cell death (ligand) 1 [PD-(L)1] and cytotoxic T lymphocyte antigen 4 (CTLA-4) signals have become the routine clinical treatment regimens for multiple cancer types [12,13]. This evidence concerns the gene CD274 and cancer.